Marinus Pharmaceuticals, Inc. Overview
Pro stress-test →Marinus Pharmaceuticals is a pharmaceutical company focused on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders, such as status epilepticus, CDKL5 deficiency disorder, and tuberous sclerosis complex. The company's lead product is ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder.
Strategic Profile
Pro stress-test →Marinus Pharmaceuticals was acquired by Immedica Pharma on February 7, 2025. As of February 7, 2025, Marinus Pharmaceuticals operates as a subsidiary of Immedica Pharma AB. The company now operates under Swedish rare disease ownership, positioning itself within a specialized pharma ecosystem focused on rare neurological conditions.
Competitive Landscape
Pro stress-test →Marinus competes in the ultra-rare epilepsy/seizure disorder therapeutics space. Competitors include ACADIA Pharmaceuticals, Alnylam Pharmaceuticals, SAGE Therapeutics, Vertex Pharmaceuticals, and Annovis Bio, among approximately 63 competitors. The company faces significant competition from better-capitalized biotech firms and larger pharma companies developing seizure disorder treatments.
Industry Context
Marinus Pharmaceuticals, Inc. operates in Biopharmaceuticals - Neuropsychiatric/Rare Seizure Disorder Therapeutics.
Key facts
Founded: 2003 · Headquarters: Radnor, Pennsylvania · Employees: 166 · Market cap: $30.0M